Southwestern internal medicine conference: restenosis: the Achilles heel of coronary angioplasty.
Percutaneous transluminal coronary angioplasty has become the treatment of choice for many patients with symptomatic coronary artery disease. Increased experience with the procedure and improvements in equipment have resulted in high initial success rates; however, a significant number of patients develop restenosis. Insights into the pathophysiologic mechanisms of restenosis have led to the use of various pharmacologic agents and devices to prevent its occurrence. Although many have been successful in decreasing the incidence of restenosis in animal studies, none has yet proven successful in decreasing the incidence of restenosis in humans. Newer approaches and novel therapies are needed to prevent restenosis after percutaneous transluminal coronary angioplasty.